Video: Immunotherapy Tie-Ups Key For Future Of ADC Space
This article was originally published in Scrip
Executive Summary
Richard Onyett, business development director of ADC Therapeutics, chats to Mike Ward, global director of content for Informa Pharma Insights, about developments in the area of antibody drug conjugates (ADCs), a field that seems to have been overshadowed by the recent immunotherapy boom. They discuss how the two fields will combine in the future in oncology and where derailed ADC companies went wrong.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.